Welcome to Drug and Alcohol Treatment
| ||
Drug Treatment Ankylosing Spondylitis Article
This is a selection made from among articles on Drug Treatment Ankylosing Spondylitis. For a permanent link to this article, or to bookmark it for future reading, click here.
Student Drug Testing In America
from: The sustained campaign for a drug free America is taking a new turn these days. After the invasion of drug testing into the workplace, now it is time for testing to expand into schools. Student drug testing is expected to reduce the tendency of teenagers to start abusing drugs and aims at nipping the problem at the bud with an emphasis on prevention.First of all, student drug testing aims at preventing adolescents from being initiated into drug abuse. The possibility of being detected in a student drug testing campaign is expected to be deterrent strong enough to convince them to abstain from succumbing to peer pressure and using drugs. Student drug testing will also identify drug abusers in their adolescence and let their counselors and parents intervene very early to help the student recover from the habit before it is too late. The students who have already developed a dependence on drugs could be easily detected and referred for treatment or rehabilitation programs.
It would be very helpful if a person is found and helped during the initial stages of his addiction since the possibility of his recovery decreases with his dependency on the drug. Most people start experimenting with drugs when they are in school. Although this is considered natural and safe as long as they don’t slip into an addiction, these innocent experiments have the inclination to transform into accidents, violent incidents or overdose. Student drug testing aims to discourage experimentation among the students to reduce the risk.
It is common to neglect the amount of drug abuse happening among students by ignoring the facts. Most people don’t understand the impact that student drug testing could make because they do not comprehend the extent of the problem that we are trying to solve. At least 50% of 12th graders are found to have used drugs once in their life and 10% admit to using Marijuana on a monthly basis.
For a school to start off on implementing a student drug testing program, first it needs to analyze the requirement it. It needs to figure out the level of drug abuse in the community as a whole and within the students of that school. Small surveys could be conducted among the students and their parents to judge the level of need for such a program. If the need for drug testing is clear, then the school needs to find funding for the project. A lot of schools are already availing themselves of funding from the Department of Education for student drug testing as a part of the Safe and Drug Free Schools Program.
A student drug testing program alone cannot play the whole game. Detection of impaired individuals should go hand in hand with intervention and treatment programs. An individual detected to be abusing drugs through a student drug testing program should undergo intervention by his parents, teachers and counselors enabling him to return to a normal socially productive life. Without this we stand to lose all benefits of the student drug testing programs.
Once a program for student drug testing has been formulated and implemented, it will act as a deterrent against drug abuse for youngsters in the country. When we separate the young and impressionable from initiation into drug abuse, what we achieve is a new generation that is clean from the effects of drugs. There has never been a better investment in the future.
About Author
This Article is written by Lena Butler, the author of TestCountry Health Information Resources, a longer version of this article is located at Student Drug Testing in America, and resources from other home health and wellness testing articles are used such as Substance Abuse & Drug Addiction.
Source: ArticleTrader.com
Drug Treatment Ankylosing Spondylitis Specific links
Drug Treatment Ankylosing Spondylitis News
Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic ... - MarketWatch (press release)
Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic ... MarketWatch (press release) The report provides an in-depth analysis of the top four arthritis therapeutic indications which are osteoarthritis, rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, Furthermore, it also includes the market forecasts and treatment ... |
J&J's Simponi Helps Colitis Patients In Clinical Trial - Wall Street Journal
J&J's Simponi Helps Colitis Patients In Clinical Trial Wall Street Journal Simponi, which was introduced in 2009, is currently approved to treat signs and symptoms of moderate to severe rheumatoid arthritis, active psoriatic arthritis and active ankylosing spondylitis. Simponi is known as an anti-tumor necrosis factor, ... New Phase 3 Study Results Show Anti-TNF SIMPONI® Induced Clinical Response in ... JNJ Updates: Positives For Xarelto & Simponi |
IL-17 Blocker Promising for Spondylitis - MedPage Today
IL-17 Blocker Promising for Spondylitis MedPage Today Explain that a fully humanized monoclonal antibody targeting the IL-17 pathway was effective in producing a 20% improvement at week six in a small phase II study of patients with previously treated ankylosing spondylitis. Note that activity appeared to ... |
Body mass index influences the response to infliximab in ankylosing spondylitis - 7thSpace Interactive (press release)
Body mass index influences the response to infliximab in ankylosing spondylitis 7thSpace Interactive (press release) The aim of this study was to determine whether body mass index (BMI) affects response to infliximab (IFX) in ankylosing spondylitis (AS) patients. Methods: In 155 patients retrospectively included with active AS, the BMI was calculated before ... |
Worcester Doctor on Leading Edge of Clinical Trials - GoLocal Worcester
 GoLocal Worcester | Worcester Doctor on Leading Edge of Clinical Trials GoLocal Worcester With a staff of nine, the group currently working on five different studies for rheumatoid arthritis, a long term study for Crohn's disease, two studies for ankylosing spondylitis (inflammation of the bones and joints in the spine), one for psoriatic ... |
POZEN Reports PA32540 / PA8140 Updates and First Quarter 2012 Financial Results - MarketWatch (press release)
POZEN Reports PA32540 / PA8140 Updates and First Quarter 2012 Financial Results MarketWatch (press release) The Company has recently completed a Phase 1 study to assess the bioequivalence of PA32540 to enteric-coated aspirin 325 mg using acetylsalicylic acid (ASA) as the analyte as requested by the US Food and Drug Administration (FDA) and believes that the ... |
Protalix BioTherapeutics to Review FDA Approval of ELELYSO(TM) - MarketWatch (press release)
Protalix BioTherapeutics to Review FDA Approval of ELELYSO(TM) MarketWatch (press release) ... announced today the Company has scheduled a conference call and webcast for Wednesday, May 2, 2012 at 8:00 AM EDT to review the US Food and Drug Administration's approval of ELELYSO(TM) for the treatment of Type 1 Gaucher disease. |
Questcor: Acthar Will Lead Stock To New Highs In 2013 - Seeking Alpha
Questcor: Acthar Will Lead Stock To New Highs In 2013 Seeking Alpha These include infantile spasms, nephrotic syndrome, multiple sclerosis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, systematic sarcoidosis, certain ophthalmic diseases and more. |
Protalix BioTherapeutics to Present at Three Upcoming Healthcare Conferences - MarketWatch (press release)
Protalix BioTherapeutics to Present at Three Upcoming Healthcare Conferences MarketWatch (press release) Protalix's first approved product manufactured by ProCellEx, ELELYSO(TM) (taliglucerase alfa), was approved for marketing by the US Food and Drug Administration on May 1, 2012 and is partnered with Pfizer for worldwide development and commercialization ... |
IL-17 Antibody May Have Role in Arthritis - MedPage Today
IL-17 Antibody May Have Role in Arthritis MedPage Today There has been an extensive proof-of-concept program for secukinumab, including a similar study evaluating the drug for ankylosing spondylitis, he said. In the rheumatoid arthritis study, 237 patients with active disease despite treatment with ... |